With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29, shareholders and prospective investors should be on alert. AbbVie is in the middle of transitioning its revenue base away from dependence on its blockbuster drug Humira, as its exclusivity protections are starting to expire outside the U.S. That means the company's stock is in a particularly sensitive time, as the prospective replacements for Humira are still in the process of ramping up. The earnings report will likely give investors updates on progress in the clinical trial pipeline, but the main dish will be the story about the pace of its revenue growth in Humira's replacements, or lack thereof.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting